Case Reports in Hematology (Jan 2021)

Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations

  • Maria Kaparou,
  • Zbigniew Rudzki,
  • Hannah Giles,
  • Vidhya Murthy,
  • Swathy Srinath,
  • Rebecca Lloyd,
  • Maria Zahid Ahmed,
  • Beena Salhan,
  • Saleena Chauhan,
  • Bhuvan Kishore,
  • Richard Lovell,
  • Claire Horgan,
  • Shankara Paneesha,
  • Evgenia Xenou,
  • Anand Lokare,
  • Joanne Ewing,
  • Hansini Dassanayake,
  • Emmanouil Nikolousis,
  • Alexandros Kanellopoulos

DOI
https://doi.org/10.1155/2021/8843063
Journal volume & issue
Vol. 2021

Abstract

Read online

The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection.